Health
Monoclonal antibodies can help high-risk people with COVID-19. But getting the drug to patients remains challe – The Philadelphia Inquirer
Demand for the drugs, which are the only approved treatment for high-risk patients who don’t need to be in the hospital, is lower than expected.
Back in December, the big worry about two newly approved treatments for early COVID-19 was that demand would far outstrip supply.
After all, some famous men had taken monoclonal antibodies after they were infected in the fall some of them before the drugs received emergency-use authorization and became highly visible converts.
Former President Donald Trump called a drug made by Regeneron a cure. (He was also given other treatments that may have helped him recover.) Ben Carson, former secretary of…
-
General22 hours agoDonald Trump’s initial 10 per cent tariff takes effect
-
General21 hours agoJaguar Land Rover in UK pauses shipments to US
-
General18 hours agoTexas opens probe into Kellogg’s health claims, dyes
-
General17 hours agoAustralian share market set to dive as threat of US recession grows